|
1. Gabbard GO. Mind and brain in psychiatric treatment.
In: Gabbard GO, editor. Treatments of psychiatric disorders. 3rd
ed. Washington (DC): American Psychiatric Press; 2001. p 3–20.
2. Masters WH, Johnson VE. Human sexual response. Boston:
Little Brown; 1966.
3. Masters WH, Johnson VE. Human sexual inadequacy.
Boston: Little Brown; 1970.
4. Segraves RT. Historical and international context
of nosology of female sexual disorders. J Sex Marital Ther 2001;27:205–8.
5. Segraves RT . Psychiatric drugs and inhibited female
orgasm. J Sex Marital Ther 1988;14:202–7.
6. Wyatt RJ, Fram DH, Buchbinder R. Treatment of intractable
narcolepsy with a monoamine oxidase inhibitor. J Clin Psychopharmacol
1971;85:987–91.
7. Kotin J, Wilbert D. Thioridazine and sexual dysfunction.
Am J Psychiatry 1976;133:82–5.
8. Shifren JL, Braunstein GD, Simon JA, Casson PR,
Buster JE, Redmond GP, and others. Transdermal testosterone treatment
in women with impaired sexual function after oophorectomy. N Engl
J Med 2000;343:682–8.
9. Basson R, McInnes R, Smith M, Hodgson G, Spain T,
Koppiker N. Efficacy and safety of sildenafil in estrogenized women
with sexual dysfunction. Obstet Gynecol 2000;S54.
10. Rosen R, Brown C, Heiman S, Leiblum S, Meston C,
Shabsigh R, Ferguson D, D’Agostino R. The Female Function Index
(FSFI): a multidimensional self-report instrument for the assessment
of female sexual function. J Sex Marital Ther 2000;26:191–208.
11. McGahuey CA, Gelenburg AJ, Laukes CA, Moreno FA,
Delgado PL, McKnight KM, and othes. The Arizona Sexual Experience
Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;27:25–40.
12. Labrie F. Androgen deficiency syndrome in women:
role of androgens and their precursor DHEA in women. Paper presented
at the Female Sexual Function Forum; October, 2001; Boston (MA).
13. Guay AT . Serum androgen and androgen precursor
hormone levels in women with and without sexual dysfunction. Paper
presented at the Female Sexual Function Forum; October, 2001; Boston
(MA).
14. Plaut SM. New diagnostic categories for female
sexual dysfunction: does the falling tree make a sound if no one
is there to hear it? J Sex Marital Ther 2001;27:193–6.
15. Vroege JA, Gijs L, Hengeveld MW. Classification
of sexual dysfunctions in women. J Sex Marital Ther 2001;27:237–44.
16. Basson R, Berman J, Burnett A, Derogatis L, Fergusin
D, Fourcroy J, and others. Report of the International Consensus
Development Conference on female sexual dysfunction: definitions
and classifications. J Sex Marital Ther 2001;27:83–94.
17. Laumann EO, Gagnon JH, Michael RT, Michaels S.
The social organization of sexuality: sexual practices in the United
States. Chicago: University of Chicago Press; 1994.
18. Laumann EO, Paik A, Rosen RC . Sexual dysfunction
in the United States: prevalence and predictors. JAMA 1999;281:537–44.
19. Dunn KM. Association of sexual problems with social,
psychological, and physical problems in men and women: a cross sectional
survey. J Epidemiol Community Health 1999;53:144–8.
20. Dunn KM. Satisfaction in the sex life of a general
population sample. J Sex Marital Ther 2000;26:141–51.
21. Fugl-Meyer KS. Epidemiology of female sexual function.
Paper presented at Female Sexual Function Forum; October, 2001;
Boston (MA).
22. Segraves KB, Segraves RT. Hypoactive sexual desire
disorder: prevalence and comorbidity in 906 patients. J Sex Marital
Ther 1991;17:1–9.
23. Lindal E, Stefansson JG. The lifetime prevalence
of psychosocial dysfunction among 55- to 57-year olds in Iceland.
Soc Psychiatry Psychiatr Epidemiol 1993;28:91–5.
24. Goodwin FK, Jamison KR. Manic depressive illness.
New York: Oxford University Press; 1990.
25. Lyketsos GC, Sakka P, Mailis A. The sexual adjustment
of chronic schizophrenics: a preliminary study. Br J Psychiatry
1983;143:376–82.
26. Miller LJ, Finnerty M. Sexuality, pregnancy and
childrearing among women with schizophrenia-spectrum disorders.
Psychiatr Serv 1996;47:502–6.
27. Gift TE, Wynnne LC, Harder D. Sexual life events
and schizophrenia. Compr Psychiatry 1988;29:151–6.
28. Aizenberg D, Sigler M, Zemishlany Z, Weizman A.
Lithium and male sexual function in affective patients. Clin Neuropharmacol
1996;19:515–9.
29. Kockott G, Pfeiffer W . Sexual disorders in nonacute
psychiatric outpatients. Compr Psychiatry 1996;37:56–61.
30. Raboch JS, Faltus F. Sexuality of women with anorexia
nervosa. Acta Psychiatr Scand 1991;84:9–11.
31. Morgan JF, Lacey JH, Reid F. Anorexia nervosa:
changes in sexuality during weight restoration. Psychosom Med 1999;61:541–5.
32. Wiederman MW, Pryor T, Morgan CD. The sexual experience
of women diagnosed with anorexia nervosa and bulimia nervosa. Int
J Eat Disord 1996;19:109–18.
33. Minnen AV, Kampman M. The interaction between anxiety
and sexual functioning: a controlled study of sexual functioning
in women with anxiety disorders. Sexual and Relationship Therapy
2000;15:47–57.
34. Mathew R, Weinman M. Sexual dysfunction without
tricyclics in depression. Arch Sex Behav 1982;11:323–8.
35. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual
dysfunction before antidepressant therapy in major depression. J
Affect Disord 1999;56:210–18.
36. Kivela SL, Pahkala K. Clinician-rated symptoms
and signs of depression in aged Finns. Int J Soc Psychiatry 1988;34:274–84.
37. Kivela SL, Pahkala K. Symptoms of depression in
old people in Finland. Zeitschrift fur Gerontologie 1988;21:257–63.
38. Schreiner-Engel P, Schiavi R. Lifetime psychopathology
in individuals with low sexual desire. J Nerv Ment Dis 1986;174:646–51.
39. Segraves RT. Sexual side effects of psychotropic
agents. In: Halaris A, editor. Bailliere’s Clinical Psychiatry.
London: WB Saunders; 1997. p 153–70.
40. Segraves RT. Psychiatric drugs and orgasm in the
human female. J Psychosom Obstet Gynec 1985;4:125–8.
41. Segraves RT, Kavoussi R, Hughes A, Batey S, Johnston,
Donahue R, and others. Evaluation of sexual functioning in depressed
outpatients: a double blind comparison of sustained release bupropion
and sertraline treatment. J Clin Psychopharmacol 2000;20:122–6.
42. Nkanginieme I, Segraves RT. Neuropsychiatric aspects
of sexual disorders. In: Fogel B, editor. Neuropsychiatry. Baltimore:
Williams and Wilkins; Forthcoming.
43. Riley A, Riley E. The effect of single dose diazepam
on sexual response induced by masturbation. Sex Martial Therapy
1986;1:49–53.
44. Segraves RT. The effects of minor tranquilizers,
mood stabilizers and antipsychotics on sexual function. Primary
Psychiatry 1999;6:37–40.
45. Harrison W, Rabkin J, Erhardt A, Stewart J, McGrath
P, Quitkin E. Effect of antidepressant medication on sexual function:
a controlled study. J Clin Psychopharmacol 1986;6:144–9.
46. Monteiro W, Noshirvani H, Marks I, Lelliott P.
Anorgasmia from clomipramine in obsessive compulsive disorder: a
controlled trial. Br J Psychiatry 1987;151:107–12.
47. Zajecka J, Mitchell S, Fawsett J. Treatment-emergent
changes in sexual function with selective serotonin reuptake inhibitors
as measured with the Rush Sexual Inventory. Psychopharmacol Bull
1997;33:755–60.
48. Labbate LA, Grimes J, Hines A, Oleshansky MA, Arana
G. Sexual dysfunction induced by serotonin reuptake antidepressants.
J Sex Marital Ther 1998;24:3–12.
49. Shen WW, Hsu JH. Female sexual side effects with
selective serotonin reuptake inhibitors: a descriptive clinical
study of 33 patients. Int J Psychiatry Med 1995;25;239–48.
50. Montejo AI, Llorca G, Izquierdo JA, Ledesma A,
Bousono M, Calcedo A, and others. SSRI-induced sexual dysfunction.
Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective,
multicenter and descriptive clinical study of 344 patients J Sex
Marital Ther 1997;23:176–94.
51. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier
B. Effect of SSRI antidepressants on ejaculation: a double-blind,
randomized, placebo-controlled study with fluoxetine, fluvoxamine,
paroxetine and sertraline. J Clin Psychopharmacol 1998;18:274–81.
52. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi
JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment
with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin
Psychiatry 2000;61:276–81.
53. Farah A. Relief of SSRI-induced sexual dysfunction
with mirtazapine treatment. J Clin Psychiatry 1999;60:260–1.
54. Clayton A, Leadbetter R, Bass K, Bolden-Watson
C, Donahue R, Jamerson B, and others. Antidepressant-associated
sexual dysfunction: risk factors. Poster presentation at New Clinical
Drug Evaluation Unit; May, 1999; Boca Raton (FL).
55. Ferguson JM, Shrivastava RK, Stahl SM, Hartford
JT, Borian F, Ieni J, and others. Reemergence of sexual dysfunction
in patients with MDD: double-blind comparison of nefazodone and
sertraline. J Clin Psychiatry 2001;62:24–9.
56. Croft H, Settle E, Houser T, Batey S, Donahue R,
Ascher J. A placebo-controlled comparison of the antidepressant
and sexual functioning aspect of bupropion sustained release and
sertraline. Clin Ther 1999;21:643–58.
57. Segraves RT, Croft H, Kavoussi R, Ascher J, Batey
S, Foster V, and others. Bupropion sustained release (SR) for the
treatment of hypoactive sexual desire disorder (HSDD) in nondepressed
women. J Sex Marital Ther 2001;27:303–16.
58. Walker PW, Cole J, Gardner E, Hughes A, Johnston
A, Batey S, and others. Improvement in fluoxetine-associated sexual
dysfunction in patients switched to bupropion. J Clin Psychiatry
1993;54:459–65.
59. Clayton DO, Shen WW. Psychotrophic drug-induced
sexual function disorders. Drug Safety 1998;19:299–312.
60. Rosen RC, Lane RM, Menza M. Effects of SSRIs on
sexual function: a critical review. J Clin Psychopharmacol 1999;19:67–85.
61. Aizenberg D, Noar S, Zemishlany Z, Weizman A. The
serotonin antagonist mianserin for treatment of serotonin reuptake
inhibitor induced sexual dysfunction in women: an open label add
on trial. Clin Neuropharmacol 1999;22:347–50.
62. Balon R. Fluoxetine-induced sexual dysfunction
and yohimbine. J Clin Psychiatry 1993;54:161.
63. Shrivastava R, Shrivastava S, Overweg N. Amantadine
in the treatment of sexual dysfunction associated with selective
serotonin reuptake inhibitors. J Clin Psychiatry 1995;15:83–4.
64. Riley A, Riley E. Cyproheptadine and antidepressant-induced
anorgasmia. Br J Psychiatry 1986;148:217–8.
65. Gitlin MJ. Treatment of sexual side-effects with
dopaminergic agents. J Clin Psychiatry 1995;56:124.
66. Pies R. Safety of sildenafil for antidepressant
related sexual dysfunction. J Clin Psychiatry 1999;60:792.
67. Berk M. Serotonergic targets in the treatment of
antidepressant induced sexual dysfunction: a pilot study of grnaisetron
and sumatriptan. Int Clin Psychopharmacol 2000;15:291–5.
68. Norden MJ. Buspirone treatment of sexual dysfunction
associated with selective serotonin reuptake inhibitors. Depression
1994;2:109–12.
69. Ashton A, Rosen R. Bupropion as an antidote for
serotonin reuptake inhibitor induced sexual dysfunction. J Clin
Psychiatry 1998;59:112–5.
70. Nelson EB. A placebo-controlled crossover trial
of granisetron in SRI- induced sexual dysfunction. J Clin Psychiatry
2001;62:469–73.
71. Clayton A, McGarvey EL, Warncok J, Kornstein S,
Pinkerton RC. Poster presentation at New Clinical Drug Evaluation
Unit; May, 1999; Boca Raton (FL).
72. Michelson D, Bancroft J, Targum S, Kim Y, Tepner
R. Female sexual dysfunction associated with antidepressant administration:
a randomized , placebo-controlled study of pharmacologic intervention.
Am J Psychiatry, 2000;157:239–43.
73. Landen M, Eriksson E, Agren H, Fahlen T. Effect
of buspirone on sexual dysfunction in depressed patients treated
with selective serotonin reuptake inhibitors. J Clin Psychopharmacol
1999;19:268–71.
74. Nurnberg G, Lauriello J, Hensley P, Parker L, Keith
S. Sildenafil for iatrogenic serotonergic antidepressant medication-induced
sexual dysfunction in four patients. J Clin Psychiatry 1999;60:33–5.
75. Baldwin D. Schizophrenia, antipsychotic drugs and
sexual function. Primary Care Psychiatry 1997;3:115–23.
76. Shen WW, Park S. Thioridazine induced inhibition
of female orgasm. Psychiatry J Univ Ottawa 1982;7:249–51.
77. Dickson R, Glazer W. Neuroleptic-induced hyperprolactinemia.
Schizophr Bull 1999;35:75–86.
78. Dickson R, Seeman M, Corenblum B. Hormonal side
effects in women: typical versus atypical antipsychotic treatment.
J Clin Psychiatry 2000;61:10–5.
79. Ghadirian A, Choviard G. Sexual dysfunction and
plasma prolactin levels in treated schizophrenic outpatients. J
Nerv Ment Dis 1982;10:463–73.
80. Hummer M, Kemmler G. Sexual disturbances during
clozapine and haloperidal treatment for schizophrenia. Am J Psychiatry
1999;56:631–3.
81. Covington L, Cola P. Clozapine versus haloperidal
on serum plasma concentrations. Sexuality and Disability 2000;18:41–8.
82. Kearns A, Goff D, Hyaden D, Daniels G. Risperidone
associated hyperprolactinemia. Endocrine Practice 2000;6:425–9.
83. Montejo A, Llorca G. New antipsychotic induced
sexual dysfunction: comparative incidence with risperidone and olanzapine
using a questionnaire. American Psychiatric Association, New Research;
1998. p 152–3.
84. Gazzola L, Opler L. Return of menstruation after
switching from risperidone to olanzapine. J Clin Psychopharmacol
1998;18:486–7.
85. Marken P, Hyakal R, Fisher J. Management of psychotropic
induced hyperprolactinemia. Clin Pharmacy 1992;11:851–6.
86. Tollin S. Use of the dopamine agonists bromocriptine
and cabergoline in the management of risperidone induced hyperprolactinemia
in patients with psychotic disorders. J Endocrinol Invest 2000;23:765–70.
87. Isojarvi J, Repo M, Pakarinen A, Lukkarinem O,
Myllyla VV. Carbamazepine, phenytoin, sex hormones, and sexual function
in men with epilepsy. Epilepsia 1995;36:366–70.
88. Tiefer L. The selling of female sexual dysfunction.
J Sex Marital Ther 2001;27:625–8.
89. Bartik B, Goldberg J. Female sexual arousal disorder.
In: Leiblum SR, Rosen RC, editors. Principles and practice of sex
therapy. New York: Guilford; 2000. p 85–117.
90. Becher EF, Bechara A, Casabe A. Clitoral hemodynamic
changes after a topical application of alprostadil. J Sex Marital
Ther 2001;27:405–10.
91. Islam A, Mitchel J, Rosen R, Phillips N, Ayers
C, Ferguson D, and others. Topical alprostadil in the treatment
of female sexual arousal disorder: a pilot study. J Sex Marit Ther
2001;27:531–40.
92. Basson R. Female sexual response: the role of drugs
in the management of female sexual dysfunction. Obstet Gynecol 2001;98:350–3.
93. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal
women affected by sexual arousal disorder treated with sildenafil:
a double-blind cross-over placebo-controlled study. British Journal
of Obstetrics and Gynecology 2001;108:623–8.
94. Billips KL, Berman L, Berman J, Metz M, Glennon
M, Goldstein I. A new non-pharmacological vacuum therapy for female
sexual dysfunction. J Sex Marital Ther 2001;27:435–42.
95. Segraves RT, Croft H, Kavoussi R, Ascher JA, Batey
SR, Foster VJ, and others. Bupropion sustained release (SR) for
the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed
women. J Sex Marital Ther 2001;27:303–16.
96. Sherwin BB. Use of combined estrogen-androgen preparations
in the postmenopause: evidence from clinical studies. Int J Fertil
Womens Med 1998;43:98–103.
97. Shifren J, Braunstein G, Simon J, Casson P, Buster
J, Redmond G, and others. Transdermal testosterone treatment in
women with impaired sexual function after oophorectomy. N Engl J
Med 2000;343:1–8.
98. Tuiten A, Van Honk J, Koppeschaar H, Bernaards
C, Thijssen J. Time course of effects of testosterone administration
on sexual arousal in women. Arch Gen Psychiatry 2000;57:149–53.
--------------------------------------------------------------------------------
Manuscript received and accepted April 2002.
Address for correspondence: Dr RT Segraves, Dept of Psychiatry,
MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH
44109
e-mail: rsegraves@metrohealth.org
|
